Public Reporting Information

For general questions or additional information about Accountable Care Organizations, please visit www.medicare.gov/acos.html or call 1-800-MEDICARE (1-800-633-4227). TTY users should call 1-877-486-2048. 

The Hackensack Alliance ACO provides the following information in accordance with Medicare Shared Savings Program (MSSP) regulations at 42 CFR §425.308.

ACO Name and Location
Name: Hackensack Physician-Hospital Alliance ACO, LLC (dba Hackensack Alliance ACO)
Location: Hackensack Meridian Health – 30 Prospect Avenue – 3 St. John Room 3844 – Hackensack, NJ 07601
Email: ACOInfo@HackensackMerdian.org

ACO Primary Contact
Name: Morey Menacker, DO
Email: Morey.Menacker@HackensackMeridian.org
Telephone: 551-996-4330
Facsimile: 551-996-0801

 

ORGANIZATIONAL INFORMATION

ACO Participants
BERGEN GASTROENTEROLOGY, PC*
DR ANTHONY M PASTENA LLC*
FOREST HEALTHCARE ASSOCIATES, PC*
GARY SCHWARTZ MD*
HACKENSACK UNIVERSITY MEDICAL GROUP PC*
INTEGRATED MEDICAL ASSOCIATES LLC*
MEDICAL ASSOCIATES OF ENGLEWOOD PC*
MONTCLAIR HOSPITAL LLC*
MOUNTAINVIEW MEDICAL GROUP, PC*
OLD HOOK MEDICAL ASSOCIATES, LLC*
OM MEDICAL CENTER, LLC*
PALISADES MEDICAL BILLING dba PALISADES MEDICAL ASSOCIATES*
PREMIER MEDICAL ALLIANCE LLC*
SHARAD SAHU MD*
SHRENIK G SHAH MD PC*
SUMMIT AVENUE MEDICAL PA*

NOTE: Participants involved in a joint venture between ACO professionals and hospitals are identified by an asterisk (*) next to their names on the above ACO Participant list


 

ACO Governing Body

NAME

ROLE

MEMBERSHIP TYPE

ACO PARTICIPANT

Dr. Peter Gross

Non-Voting

Other - Chair, ACO Board of Managers

N/A

Mr. Robert Garrett

Voting

Other - Hackensack Meridian Health

N/A

Mr. Mark Sparta

Voting

Other - Hackensack Meridian Health

N/A

Mr. Bernard Bober

Voting

Other - Medicare Beneficiary Representative

N/A

Dr. Morey Menacker

Voting

ACO Participant Representative

Forest Healthcare Associates, PC

Dr. Edward Gold

Voting

ACO Participant Representative

Old Hook Medical Associates, LLC

Dr. Azzam Baker

Voting

ACO Participant Representative

Hackensack University Medical Group PC

Dr. Ihor Sawczuk

Voting

ACO Participant Representative

Hackensack University Medical Group PC

Dr. Eric Avezzano

Voting

ACO Participant Representative

Premier Medical Alliance LLC

Dr. Kenneth Faistl

Voting

ACO Participant Representative

Montclair Hospital LLC

Dr. Michael Giuliano

Voting

ACO Participant Representative

Old Hook Medical Associates, LLC

Dr. Sharad Sahu

Voting

ACO Participant Representative

Shard Sahu MD

Dr. Edward Prins

Voting

ACO Participant Representative

Summit Avenue Medical PA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Key ACO Clinical and Administrative Leadership

KEY ACO LEADERSHIP POSITION

NAME

President & CEO, Hackensack Physician-Hospital Alliance ACO LLC

Dr. Morey Menacker

VP & Medical Director, Hackensack Physician-Hospital Alliance ACO LLC

Dr. Edward Gold

Compliance Officer, Hackensack Physician-Hospital Alliance ACO LLC

Mr. Thomas Flynn

Quality Assurance/Improvement Officer, Hackensack Physician-Hospital Alliance ACO LLC

Dr. Edward Gold

Administrative and Clinical Director, Hackensack Physician-Hospital Alliance ACO LLC

Ms. Denise Patriaco

 

 

 

 

 

 

 

 

 

 

ACO Committees and Committee Leadership

COMMITTEE NAME

LEADERSHIP

Executive Committee

Dr. Peter Gross, Chair

Quality and Safety Committee

Dr. Morey Menacker, Chair

Compliance and Credentials Committee

Dr. Sharad Sahu, Chair

Finance Committee

Dr. Eric Avezzano, Chair

 

 

 

 

 

 

 

Identification of the Types of ACO Participants or Combinations of Participants that Formed the ACO

  • Partnership or joint venture arrangement between hospitals and ACO professionalsQuality Performance Results

 

 

SHARED SAVINGS AND LOSSES

Amount of Shared Savings/Losses

  • Agreement period beginning 2013, Performance Year 1: $5,266,358
  • Agreement period beginning 2013, Performance Year 2014: $2,832,988
  • Agreement period beginning 2013, Performance Year 2015: $15,640,878
  • Agreement period beginning 2016, Performance Year 2016: TBD

 

How Shared Savings Are Distributed

  • Agreement period beginning 2013, Performance Year 1
    • Proportion invested in infrastructure: 40%
    • Proportion invested in redesigned care process/resources: 10%
    • Proportion of distribution to ACO participatnts: 50%
  • Agreement period beginning 2013, Performance Years 2014, 2015
    • Proportion invested in infrastructure: 40%
    • Proportion invested in redesigned care process/resources: 10%
    • Proportion of distribution to ACO participatnts: 50%
  • Agreement period beginning 2016, Performance Year 2016
    • Proportion invested in infrastructure: TBD
    • Proportion invested in redesigned care process/resources: TBD
    • Proportion of distribution to ACO participatnts: TBD

 

PAYMENT RULE WAIVERS

WAIVER USED

REPORTING WAIVER USE

No

No, our ACO does not utilize the SNF 3-Day Rule Waiver.

 

 

 

QUALITY PERFORMANCE RESULTS

2015 Quality Performance Results

Measure

Number

Measure Name

2015 Reporting Period

ACO

Performance Rate

Mean Performance

Rate (SSP-ACOs)

ACO-1

CAHPS: Getting Timely Care, Appointments, and Information

82.14

80.61

ACO-2

CAHPS: How Well Your Providers Communicate

92.69

92.65

ACO-3

CAHPS: Patients’ Rating of Provider

91.48

91.94

ACO-4

CAHPS: Access to Specialists

81.03

83.61

ACO-5

CAHPS: Health Promotion and Education

58.58

59.06

ACO-6

CAHPS: Shared Decision Making

75.33

75.17

ACO-7

CAHPS: Health Status/Functional Status

71.92

72.30

ACO-34

CAHPS: Stewardship of Patient Resources*

21.24

26.87

ACO-8

Risk Standardized, All Condition Readmission

15.06

14.86

ACO-35

Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNFRM)* Readmission

20.72

18.07

ACO-36

All-Cause Unplanned Admissions for Patients with Diabetes*

58.94

54.60

ACO-37

All-Cause Unplanned Admissions for Patients with Heart Failure*

80.13

76.96

ACO-38

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions

63.18

62.92

ACO-9

Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)

1.28

1.11

ACO-10

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)

0.84

1.04

ACO-11

Percent of Primary Care Physicians who Successfully Meet Meaningful Use Requirements

80.34%

76.22%

ACO-39

Documentation of Current Medications in the Medical Record*

98.98%

84.07%

ACO-13

Falls: Screening for Future Fall Risk

74.92%

56.46%

ACO-14

Preventive Care and Screening: Influenza Immunization

76.61%

62.03%

ACO-15

Pneumonia Vaccination Status for Older Adults

63.58%

63.73%

ACO-16

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-up

88.58%

71.15%

ACO-17

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

95.45%

90.16%

ACO-18

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan

69.55%

45.25%

ACO-19

Colorectal Cancer Screening

70.42%

60.06%

ACO-20

Breast Cancer Screening

73.97%

65.67%

ACO-21

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

88.35%

70.04%

ACO-40

Depression Remission at Twelve Months*

N/A

N/A

ACO-27

Diabetes Mellitus: Hemoglobin A1c Poor Control

14.18%

20.38%

ACO-41

Diabetes: Eye Exam*

49.65%

41.05%

ACO-28

Hypertension: Controlling High Blood Pressure

80.13%

69.62%

ACO-30

Ischemic Vascular Disease: Use of Aspirin or Another Antithrombotic

92.25%

83.82%

ACO-31

Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

97.91%

87.22%

ACO-33

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)

90.21%

77.73%

CAHPS=ConsumerAssessmentofHealthcareProvidersandSystems,PQI=PreventionQualityIndicator,LVSD=leftventricularsystolic dysfunction,ACE=angiotensin-convertingenzyme,ARB=angiotensinreceptorblocker,CAD= coronaryarterydisease.

*=Measure requiredbeginningReportingYear2015.

N/A= Reportingonthe depressionremissionmeasure is notrequiredfor2015,as indicatedbyN/A

 

 

2012, 2013, and 2014 Quality Performance Results

Quality Measure

2012 Reporting Period

2013 Reporting Period

2014 Reporting Period

Measure

Number

Performance Measure

ACO Performance Rate

Mean Perf Rate for All ACOs

ACO Performance Rate

Mean Perf Rate for All ACOs

ACO Performance Rate

Mean Perf Rate for All ACOs

ACO #1

Getting Timely Care, Appointments, and Information

79.96

81.79

81.50

81.48

76.73

80.13

ACO #2

How Well Your Doctors Communicate

92.10

92.84

93.30

92.96

92.37

92.39

ACO #3

Patients’ Rating of Doctor

91.11

91.86

91.58

92.06

90.97

91.58

ACO #4

Access to Specialists

84.74

85.11

86.50

85.12

87.11

83.97

ACO #5

Health Promotion and Education

54.01

56.61

55.85

58.38

60.24

58.29

ACO #6

Shared Decision Making

71.13

73.99

74.14

74.53

71.28

74.60

ACO #7

Health Status/Functional Status

71.96

70.35

73.84

71.12

69.22

71.10

ACO #8

Risk Standardized, All Condition Readmissions

16.33

15.42

15.52

14.90

16.43

15.15

ACO #9

ASC Admissions: COPD or Asthma in Older Adults

1.17

1.13

1.07

1.17

1.03

1.08

ACO #10

ASC Admission: Heart Failure

0.84

1.09

1.05

1.20

1.19

1.19

ACO #11

Percent of PCPs who Qualified for EHR Incentive Payment

34.92%

25.70%

69.01%

66.21%

77.63%

76.71%

ACO #12

Medication Reconciliation

88.10%

72.37%

87.38%

73.56%

93.54%

82.61%

ACO #13

Falls: Screening for Fall Risk

5.58%

28.27%

35.95%

39.57%

70.35%

45.60%

ACO #14

Influenza Immunization

50.17%

50.58%

66.78%

56.93%

79.78%

57.51%

ACO #15

Pneumococcal Vaccination

36.36%

48.62%

62.44%

54.76%

72.95%

55.03%

ACO #16

Adult Weight Screening and Follow-up

51.36%

5.39%

73.28%

61.61%

92.05%

66.75%

ACO #17

Tobacco Use Assessment and Cessation Intervention

79.67%

80.12%

9269.00%

84.01%

97.70%

86.79%

ACO #18

Depression Screening

26.58%

22.48%

35.31%

31.19%

66.85%

39.27%

ACO #19

Colorectal Cancer Screening

57.17%

50.21%

67.38%

59.30%

73.84%

56.14%

ACO #20

Mammography Screening

50.08%

62.23%

65.22%

62.05%

76.38%

61.41%

ACO #21

Proportion of Adults who had blood pressure screened in past 2 years

60.75%

71.56%

94.73%

74.25%

94.83%

60.24%

ACO #22

Hemoglobin A1c Control (HbA1c) (<8 percent)

74.78%

64.46%

76.10%

68.58%

79.47%

25.41%

ACO #23

Low Density Lipoprotein (LDL) (<100 mg/dL)

61.20%

52.99%

62.37%

54.78%

67.55%

25.41%

ACO #24

Blood Pressure (BP) <140/90

71.43%

66.04%

77.12%

69.53%

76.32%

25.41%

ACO #25

Tobacco Non Use

88.01%

71.72%

87.29%

63.33%

91.72%

25.41%

ACO #26

Aspirin Use

68.23%

72.24%

91.75%

74.82%

97.73%

25.41%

ACO #27

Percent of beneficiaries with diabetes whose HbA1c in poor control (>9 percent)

15.52%

25.94%

14.58%

22.11%

9.60%

20.35%

ACO #28

Percent of beneficiaries with hypertension whose BP <140/90

67.23%

63.22%

78.23%

67.79%

82.01%

68.02%

ACO #29

Percent of beneficiaries with IVD with complete lipid profile and LDL control <100mg/dl

35.98%

52.02%

61.10%

55.44%

66.90%

57.29%

ACO #30

Percent of beneficiaries with IVD who use Aspirin or other antithrombotic

80.30%

72.60%

83.81%

76.35%

93.49%

80.79%

ACO #31

Beta-Blocker Therapy for LVSD

83.17%

79.60%

88.27%

79.82%

96.86%

82.71%

ACO #32

Drug Therapy for Lowering LDL Cholesterol

88.25%

69.67%

79.93%

71.60%

80.32%

66.90%

ACO #33

ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD

77.66%

69.71%

82.20%

69.13%

88.59%

66.90%

Note: ASC = ambulatory sensitive conditions, COPD = chronic obstructive pulmonary disease, PCP = primary care physician, EHR = electronic health record, IVD = ischemic vascular disease, LVSD = left ventricular systolic dysfunction, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CAD = coronary artery disease.

 

For more information on how to interpret scores on the above quaility performance measures, see

http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/MSSP-QM-Benchmarks.pdf



 

DISCLOSURE BY

HACKENSACK PHYSICIAN-HOSPITAL ALLIANCE ACO, LLC

(FOR PURPOSES OF MEDICARE FRAUD AND ABUSE WAIVER)
 

Hackensack Physician-Hospital Alliance ACO, LLC (the "ACO") seeks waiver protection under the federal Medicare Shared Savings Program for the following arrangement:

The ACO has entered into an arrangement with Hackensack University Medical Center ("HUMC"), as of April 1, 2016, whereby HUMC and its affiliates, HUMC Cardiovascular Partners, P.C. ("HUMCCP"), and Hackensack University Medical Group, P.C. ("HUMG"), and the cardiologists employed or otherwise engaged by HUMCCP and HUMG will provide on-call coverage and professional cardiology services to the ACO patients of HUMC (both in HUMC's emergency department and elsewhere, as needed).  The purposes of this arrangement are to improve accountability for the quality of care for the ACO's patients, by means of coordinated and integrated protocols and personnel, as well as to improve the efficiency, quality, and access to cardiac care for the ACO's chest pain patients at HUMC.  In particular, the arrangement is intended to ensure accessibility to consistent and coordinated high quality cardiac evaluation and treatment of the ACO's patients at HUMC.





 

Page Last Modified:  10/7/2016  2:45PM

 

 

 

 


close (X)